18 results about "Thionazin" patented technology

The invention belongs to the technical field of medicines, and relates to an aromatic ring thiazine derivative, in particular to structural forms such as free alkali, isomeride and pharmaceutically acceptable salt form of the compound. Methods for preparing such compounds; compositions comprising such compounds and therapeutic uses thereof. Based on a histamine PI3K delta receptor ligand, a series of compounds with novel structures are developed, a series of related biological tests are carried out on the compounds, and test results show that the compounds find novel PI3K delta high-selectivity inhibitors, have the characteristics of small toxic and side effects and low bioavailability, and have broad application prospects. The pharmaceutical composition is used for developing inhaled medicines suitable for treating respiratory system diseases such as asthma and COPD, and has important clinical significance and social value.

The application relates to a synthesis method of a phenothiazine derivative, and belongs to the technical field of synthesis in organic chemistry. A diaryl iodonium salt and N-(2-mercapto phenyl)-4-methyl benzene sulfonamide are used as starting materials, and chlorpromazine and perphenazine are obtained through a plurality of steps of substitution reaction, reduction reaction, addition reaction and deprotection reaction. In the application, the reaction raw materials are easy to obtain, the yield is high, and chlorpromazine and perphenazine can be successfully obtained.

The application discloses a green method for synthesizing [1,2] thiazine derivative, and belongs to the technical field of green chemistry and organic synthesis. The [1,2] thiazine derivative containing alkane, alkene, halogen and heterocycle is prepared under the condition of room temperature, openness and neutrality, and a catalyst is MBr x (M is Fe 2+ , Fe 3+ , Ce 3+ , etc., and x is 2-3), and the only oxidant is H2O2. The application realizes the synthesis and preparation of [1,2] thiazine derivative with H2O2 as an oxidant for the first time, and the catalytic reaction is green and sustainable, and the use of expensive and complex catalysts is avoided. The by-product is H2O, and the problems of environmental damage and low yield caused by catalytic reactions of many other strong oxidants are solved. The application has the advantages of mild reaction condition, simple reaction process, high yield, safety, environmental protection, conformity to the green chemistry concept, wider applicability, wide development prospect and application prospect, and can be widely applied in the fields of organic synthesis, medicine, pesticide and probe, etc.

The application discloses a phenothiazine compound or a pharmaceutically acceptable salt thereof, and a preparation and application thereof. 1‑5 The application can inhibit HSC-LX2 activity, and has no significant toxicity to liver cells at the dose. In-vivo and in-vitro experimental results show that CCOPTZBr has excellent anti-hepatic fibrosis activity, whether in improvement of mouse hepatic fibrosis as a whole or in inhibition of HSC proliferation and induction of activated HSC aging, and therefore CCOPTZBr can be used for preparation of an anti-hepatic fibrosis drug, and has a good drug-making prospect.

The application discloses a precise sulfonamide hapten, an artificial antigen and application thereof. The application provides two kinds of precise sulfonamide haptens, and an antibody of precise sulfonamide is prepared, which has high titer, high stability and high affinity, and provides core raw materials for establishing an immunodetection method of thiazide drugs. The application also establishes an indirect competitive ELISA immunological analysis method of a broad-spectrum thiazide drug, which has high sensitivity, the minimum detection limit (LOD) of the precise sulfonamide is 0.015 ng / mL, and the IC 50 of the six kinds of thiazide drugs ranges from 0.76 ng / ml to 358.76 ng / ml, and the method has a good application prospect in the residual detection of thiazide drugs.

The invention discloses application of phenothiazine compounds in preparation of antituberculosis drugs, and belongs to the technical field of biomedicine. The invention discloses application of phenothiazine compounds in preparation of antituberculous drugs, phenothiazine compounds X79 serve as a photosensitizer to mediate photodynamic therapy to generate active oxygen to achieve host-oriented treatment, a brand new treatment strategy is provided for infection of intracellular bacteria such as mycobacterium tuberculosis, biocompatibility is excellent, functional modification is easy to achieve, and the phenothiazine compounds X79 can be applied to preparation of antituberculous drugs. Good application prospects are realized in the field of tuberculosis treatment.

A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.

The present application relates to the technical field of perovskite solar cells, in particular to a phenothiazine SAM molecule, a hole transport layer, a perovskite solar cell and a preparation method thereof, and the core lies in designing a novel phosphoric acid-based self-assembled monolayer (SAM) based on a phenothiazine structure, using a mixed SAM system to prepare a high-efficiency trans perovskite solar cell. The phenothiazine SAM has unique energy level characteristics and a suitable dipole moment, and by mixing with a carbazole-based phosphoric acid SAM, the energy level of the hole transport layer (SAM layer) can be accurately controlled, and the contact of the SAM and the perovskite intermediate interface can be improved. The novel molecular structure helps to promote better energy level matching between the perovskite layer and the valence band, thereby improving the charge extraction efficiency. At the same time, the introduction of the hydrophilic thiophene unit can also effectively inhibit the self-aggregation behavior of the single SAM molecule during the film forming process, and improve the interface wettability.

The present invention belongs to the technical field of pharmaceuticals, relates to an aromatic ring-fused thiazine derivative, and in particular relates to a free alkali, an isomer, a pharmaceutically acceptable salt form and other structural forms of the compound, a method for preparing such compounds, and a composition comprising such compounds and the therapeutic use thereof. In the present invention, on the basis of the histamine PI3Kδ receptor ligand, a series of compounds with novel structures have been developed, and a series of related biological experiments have been carried out on the compounds. The experimental results all show that the compounds are found to be a novel type of highly selective PI3Kδ inhibitor, which combines the characteristics of low toxicity and mild side effects and low bioavailability, is used for developing inhaled drugs suitable for treating respiratory diseases such as asthma and COPD, and has important clinical significance and social values.

The present invention provides a method for the therapeutic or prophylactic treatment of microvascular cerebral disease in a subject, comprising orally administering to said subject a reduced form of a methylthioninium (MT)-containing compound, said administration providing a total daily dose of 8-200 mg of MT to the subject per day, optionally divided into two or more doses.

Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and / or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.

The present invention provides a method of treating hypertension in a hypertensive subject, the method comprising administering to the subject an amount of an angiotensin II receptor blocker (ARB), an amount of a thiazine-based or thiazine-like diuretic agent once a day, and an amount of lorenstat or a pharmaceutically acceptable salt thereof once a day, wherein these amounts taken together are sufficient to treat hypertension in the hypertensive subject.

Compounds similar to oxathiazine, processes for their synthesis, useful components for their preparation, and their applications are described. Processes for treating patients with cancer, bacterial, fungal, or viral infections through the administration of these compounds are also described. It was observed that these compounds had a significantly longer half-life than taurolidine and taurultam.

The invention discloses a phenothiazine small molecule compound as well as a preparation method and application thereof. The phenothiazine small molecule compound has the following structural formula. When the phenothiazine small molecule compound is used as a hole transport material, a volatile organic solvent (such as ethanol and the like) can be used as a solvent to be processed by a solution method, so that a device cannot be damaged, and the cost is low; and the performance of an organic photoelectric detector prepared from the phenothiazine small molecule compound as a hole transport material is superior to that of a classic hole transport material PEDOT: PSS.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.